naftopidil has been researched along with Adenoma, Prostatic in 85 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacies of naftopidil and tamsulosin in terms of reducing storage symptoms in patients with benign prostatic hyperplasia." | 9.27 | Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( Chung, JI; Hong, JH; Jung, TY; Kang, TW; Kwak, C; Kwon, SY; Lee, JY; Lee, KS; Seo, SI; Yoo, TK; Yun, SJ, 2018) |
| "Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range." | 9.24 | Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study. ( Chung, MS; Lee, SH; Yoon, BI, 2017) |
| "We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH)." | 9.22 | [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin]. ( Ito, N; Kamiyama, Y; Kanamaru, S; Kawakita, M; Matsumoto, K; Muguruma, K; Shirahase, T; Takahashi, T; Tsukazaki, H; Tsunemori, H; Utsunomiya, N, 2016) |
| "A total of 177 male patients with nocturia were included in the present study and randomized to morning or evening dosing of naftopidil." | 9.20 | Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. ( Adachi, T; Kuratsukuri, K; Nakamura, T; Nakatani, T; Ohmachi, T; Tamada, S; Tanaka, T; Yamaguchi, T; Yamamoto, S; Yoshimura, R, 2015) |
| "This was a multicenter randomized trial to investigate the clinical efficacy and the impact on sexual function of alpha-1A selective silodosin and alpha-1D selective naftopidil for treatment of benign prostatic hyperplasia." | 9.17 | Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. ( Aoki, Y; Hachiya, T; Saito, T; Takahashi, S; Yamaguchi, K; Yoshikawa, T, 2013) |
| "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil." | 9.17 | α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. ( Kakizaki, H; Numata, A; Osanai, H; Watanabe, M; Yamaguchi, S, 2013) |
| " This study aimed to compare the clinical effects of the alpha-adrenoceptor antagonist, silodosin, with those of naftopidil in patients presenting lower urinary tract symptoms associated with benign prostatic hyperplasia." | 9.17 | Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. ( Fujisawa, M; Haraguchi, T; Minayoshi, K; Miyake, H; Miyazaki, J; Morishita, S; Shigemura, K; Shirakawa, T; Tanaka, K; Yamada, Y, 2013) |
| "We compared the efficacy, safety, and patient preferences for two α1-adrenoceptor (AR) antagonists with different affinity for AR subtypes, naftopidil (Naf) and silodosin (Silo), for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (male LUTS/BPH)." | 9.16 | [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. ( Asakura, T; Hashiba, T; Jinza, S; Masuda, M; Masuko, H, 2012) |
| "A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks." | 9.15 | [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]. ( Aoki, D; Furukawa, M; Hakariya, T; Hayashi, M; Igawa, T; Kanetake, H; Matsuya, F; Nishimura, N; Nomata, K; Onita, T; Sakai, H; Shida, Y; Shiraishi, K; Shono, T; Takehara, K; Tsurusaki, T; Yogi, Y, 2011) |
| "Silodosin has a greater impact on improving PI-induced lower urinary tract symptoms than the other two agents." | 9.15 | Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. ( Baba, S; Fujita, T; Hayakawa, K; Ishiyama, H; Kimura, M; Kitano, M; Kotani, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 9.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 9.14 | Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. ( Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T, 2009) |
| "To investigate the benefit of alpha1-adrenoceptor antagonist naftopidil on the quality of life (QOL) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS)." | 9.14 | Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. ( Araki, K; Awa, Y; Egoshi, K; Ichikawa, T; Komiya, A; Mikami, K; Nakatsu, H; Naya, Y; Ohki, T; Onishi, T; Ota, S; Sato, N; Suzuki, H, 2010) |
| "We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS)." | 9.14 | A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. ( Kazama, T; Kimura, H; Nozaki, T; Okumura, A; Tsuritani, S, 2010) |
| "To examine the effect of alpha 1D/A adrenoceptor inhibitor naftopidil on health-related quality of life (QOL) in men with benign prostatic hyperplasia (BPH)." | 9.13 | Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. ( Awa, Y; Egoshi, K; Hamano, S; Ichikawa, T; Mori, I; Ohki, T; Okano, T; Ota, S; Sakurayama, Y; Suzuki, H, 2008) |
| "The clinical usefulness of naftopidil was evaluated in 122 patients with benign prostatic hyperplasia for urinary tract symptoms and signs, focused in particular on nocturia." | 9.13 | Effect of naftopidil on nocturia after failure of tamsulosin. ( Oh-oka, H, 2008) |
| "To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms." | 9.13 | [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms]. ( Gao, JP; Ge, JP; Gong, J; Ma, HQ; Shang, XJ; Wang, D; Wei, W; Xu, S; Zhang, ZY, 2008) |
| "We conducted a systematic review and meta-analysis to assess the outcomes and complications of naftopidil in treating elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and compared them with those administered with tamsulosin." | 9.12 | Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. ( Chai, Y; Che, X; Cui, Y; Zhang, Y; Zhou, Z, 2021) |
| "To compare the efficacy of two alpha(1)-adrenoceptor antagonists, alpha(1A)-adrenoceptor-selective tamsulosin hydrochloride and alpha(1D)-adrenoceptor-selective naftopidil, in the treatment of lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH)." | 9.12 | Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. ( Deguchi, T; Ishihara, S; Masue, T; Miwa, K; Nishino, Y; Takahashi, Y, 2006) |
| "The present study investigated the efficacy, safety, and utility of starting an alpha(1d)-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 9.12 | Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. ( Kumon, H; Nasu, Y; Takamoto, H; Watanabe, T; Yokoyama, T, 2006) |
| "The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH)." | 9.11 | Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. ( Kamai, T; Sakakibara, R; Tsujii, T; Uchiyama, T; Yamanishi, T; Yasuda, K; Yoshida, K, 2004) |
| "To compare the efficacy and safety of two alpha1a/alpha1d adrenoceptor (AR) antagonists with different affinity for the alpha1AR subtypes, tamsulosin and naftopidil, in the treatment of benign prostatic hyperplasia (BPH)." | 9.11 | Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. ( Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H, 2005) |
| "To evaluate the clinical efficacy and safety of Naftopidil tablet in treating benign prostatic hyperplasia." | 9.10 | [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia]. ( Ju, XB; Su, JT; Wu, HF, 2002) |
| "We studied the efficacy of naftopidil (50 mg/day) on nocturia associated with benign prostatic hyperplasia in 35 patients (62-80 years old)." | 9.10 | [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia]. ( Araki, I; Fukuzawa, S; Hashimura, T; Soeda, T; Sugino, Y; Takeuchi, H; Taki, Y, 2003) |
| "We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for benign prostatic hyperplasia patients." | 9.10 | [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia]. ( Arai, G; Hayashi, T; Hyochi, N; Kageyama, Y; Kawakami, S; Kihara, K; Kobayashi, T; Masuda, H; Okuno, T; Saito, K; Sakai, Y; Suzuki, M, 2002) |
| "Thirty-two patients with voiding dysfunction attributable to symptomatic benign prostatic hyperplasia were treated with naftopidil, an alpha 1-blocker, at doses of 25-75 mg/day for 4-6 weeks." | 9.07 | Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. ( Akimoto, S; Nagashima, K; Shimazaki, J; Tojo, M; Yamanishi, T; Yasuda, K, 1994) |
| "Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)." | 8.80 | [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000) |
| "First, disproportionality analysis compared the frequency of delirium in the adrenergic alpha-1 receptor antagonists silodosin, tamsulosin, and naftopidil." | 8.31 | Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan. ( Kawakami, Y; Kotake, K; Noritake, Y, 2023) |
| "To assess the efficacy of silodosin as second-line α-blocker monotherapy in patients with lower urinary tract symptoms as a result of benign prostatic hyperplasia." | 7.88 | Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study. ( Haga, K; Hirose, T; Ichihara, K; Iwasawa, A; Masumori, N; Miyao, N; Nishimura, M; Sasamura, H; Suzuki, N; Taguchi, K; Yamaguchi, Y, 2018) |
| "To clarify the influence of naftopidil, an α1D/A -adrenergic receptor antagonist, on the autonomic nervous system, we examined the relation between lower urinary tract symptoms (LUTS) and the plasma monoamine levels before and after naftopidil treatment in benign prostatic hyperplasia (BPH) patients." | 7.83 | Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. ( Ashitomi, K; Kadekawa, K; Matayoshi, Y; Mukoyama, H; Nishijima, S; Onaga, T; Sakumoto, M; Shimabukuro, H; Shimabukuro, S; Sugaya, K, 2016) |
| "The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH)." | 7.77 | [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy]. ( Hashimoto, Y; Hatakeyama, S; Kamimura, N; Kawaguchi, T; Koie, T; Kudo, S; Ohyama, C; Takahashi, S; Yoneyama, T; Yoshikawa, K, 2011) |
| "This study evaluated the 5-year failure rate of naftopidil (NAF) or tamsulosin hydrochloride (TAM) in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/LUTS) and compared the prognostic factor of two alpha(1)-blockers." | 7.76 | Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. ( Honda, S; Iwata, S; Kawachi, Y; Maruyama, O; Noto, K; Sakurai, T; Sugimura, S, 2010) |
| " We studied the efficacy of naftopidil an alpha 1-adrenoreceptor antagonist used for treatment of BPH for improvement of nocturia and consequent sleep disturbance." | 7.76 | [Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia]. ( Iwaki, H; Konishi, T; Narita, M; Okada, Y; Sakano, Y; Soga, H, 2010) |
| "The clinical usefulness and optimal dose of naftopidil were evaluated and discussed in 100 patients with benign prostatic hyperplasia without urinary retention." | 7.75 | Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg. ( Oh-oka, H, 2009) |
| "We examined the effectiveness of naftopidil in 81 patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)." | 7.74 | [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index]. ( Hamano, S; Murakami, S; Nakatsu, H; Naoi, M; Sekiyama, K; Suzuki, N; Tanaka, M, 2007) |
| "We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for 154 symptomatic benign prostatic hyperplasia (BPH) patients who also suffered from overactive bladder (OAB) symptoms." | 7.74 | [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder]. ( Abe, K; Egaway, S; Furuta, A; Ikemoto, I; Kishimoto, K; Kiyota, H; Kosugi, S; Shimomura, T; Shirai, H; Suzuki, Y; Takeuchi, H; Torii, S, 2007) |
| "To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice." | 7.74 | Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007) |
| "We cross-sectionally studied the incidence and impact on quality of life of ejaculatory disorders caused by alpha-1 adrenoceptor antagonists (tamsulosin or naftopidil) in patients with benign prostatic hyperplasia (BPH)." | 7.73 | [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin]. ( Furuya, R; Furuya, S; Hisasue, S; Itoh, N; Masumori, N; Ogura, H; Tsukamoto, T, 2005) |
| "We evaluated the efficacy of an alpha1a/d blocker, naftopidil, on storage symptoms in patients with benign prostatic hyperplasia (BPH), using frequency/volume charts (FVC)." | 7.73 | Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. ( Kawamura, T; Kitamura, T; Matsushima, H; Tajima, A; Takahashi, S; Tominaga, T, 2006) |
| "We compared the urethral and cardiovascular effects of silodosin (selective alpha(1A)-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective alpha(1A)/alpha(1D)-adrenoceptor antagonist) and naftopidil (selective alpha(1D)-adrenoceptor antagonist)." | 7.73 | [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. ( Hayashi, M; Kobayashi, M; Kobayashi, S; Shibata, N; Tadachi, M; Tatemichi, S; Tomiyama, Y; Yamazaki, Y, 2006) |
| "Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months." | 7.72 | [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia]. ( Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Iinuma, M; Kudou, T; Ohinata, M; Suzuki, A, 2003) |
| "Tamsulosin was more effective than naftopidil on intermittency, nocturia and quality of life scores." | 6.73 | Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. ( Hosokawa, Y; Kishino, T; Momose, H; Ono, T; Oyama, N, 2007) |
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 6.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting." | 6.58 | Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. ( Dahm, P; Gandhi, S; Hwang, EC; Imamura, M; Jung, JH; Kim, MH; Pang, R, 2018) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 6.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| "Among patients with benign prostatic hyperplasia who were treated with a alpha1-adrenoceptor blocker, we administered naftopidil (75 mg/day) for 12 weeks to 85 patients in whom the global severity was evaluated as moderate or severe." | 5.35 | [The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance]. ( Kojima, Y; Miyake, O; Oda, M; Okuyama, A; Tsujihata, M; Uchida, K; Yoshimura, K, 2009) |
| "Naftopidil was administered for three months to the patients with BPH who had nocturia with a urinary frequency of two or more times." | 5.32 | [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts]. ( Furuhata, A; Hirokawa, M; Hiromoto, Y; Ikeda, A; Kawasaki, C; Masuda, M; Nakayama, K; Satomi, Y; Shiramizu, M, 2004) |
| "To compare the efficacies of naftopidil and tamsulosin in terms of reducing storage symptoms in patients with benign prostatic hyperplasia." | 5.27 | Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( Chung, JI; Hong, JH; Jung, TY; Kang, TW; Kwak, C; Kwon, SY; Lee, JY; Lee, KS; Seo, SI; Yoo, TK; Yun, SJ, 2018) |
| "Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range." | 5.24 | Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study. ( Chung, MS; Lee, SH; Yoon, BI, 2017) |
| "We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH)." | 5.22 | [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin]. ( Ito, N; Kamiyama, Y; Kanamaru, S; Kawakita, M; Matsumoto, K; Muguruma, K; Shirahase, T; Takahashi, T; Tsukazaki, H; Tsunemori, H; Utsunomiya, N, 2016) |
| "A total of 177 male patients with nocturia were included in the present study and randomized to morning or evening dosing of naftopidil." | 5.20 | Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. ( Adachi, T; Kuratsukuri, K; Nakamura, T; Nakatani, T; Ohmachi, T; Tamada, S; Tanaka, T; Yamaguchi, T; Yamamoto, S; Yoshimura, R, 2015) |
| "This was a multicenter randomized trial to investigate the clinical efficacy and the impact on sexual function of alpha-1A selective silodosin and alpha-1D selective naftopidil for treatment of benign prostatic hyperplasia." | 5.17 | Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. ( Aoki, Y; Hachiya, T; Saito, T; Takahashi, S; Yamaguchi, K; Yoshikawa, T, 2013) |
| "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil." | 5.17 | α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. ( Kakizaki, H; Numata, A; Osanai, H; Watanabe, M; Yamaguchi, S, 2013) |
| " This study aimed to compare the clinical effects of the alpha-adrenoceptor antagonist, silodosin, with those of naftopidil in patients presenting lower urinary tract symptoms associated with benign prostatic hyperplasia." | 5.17 | Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. ( Fujisawa, M; Haraguchi, T; Minayoshi, K; Miyake, H; Miyazaki, J; Morishita, S; Shigemura, K; Shirakawa, T; Tanaka, K; Yamada, Y, 2013) |
| "Video images of the prostatic urethra were recorded during cystourethroscopy in 11 patients with benign prostatic hyperplasia (BPH) before and after treatment with an alpha-1 blocker, naftopidil." | 5.16 | Analysis of energy loss mediated by an alpha-1 blocker in patients with benign prostatic hyperplasia using a virtual urethra processed from an endoscopic video image. ( Ichikawa, T; Igarashi, T; Ishii, T; Kambara, Y; Nakamura, K; Naya, Y; Sakamoto, S; Sazuka, T; Yamanishi, T, 2012) |
| "We compared the efficacy, safety, and patient preferences for two α1-adrenoceptor (AR) antagonists with different affinity for AR subtypes, naftopidil (Naf) and silodosin (Silo), for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (male LUTS/BPH)." | 5.16 | [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. ( Asakura, T; Hashiba, T; Jinza, S; Masuda, M; Masuko, H, 2012) |
| "A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks." | 5.15 | [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]. ( Aoki, D; Furukawa, M; Hakariya, T; Hayashi, M; Igawa, T; Kanetake, H; Matsuya, F; Nishimura, N; Nomata, K; Onita, T; Sakai, H; Shida, Y; Shiraishi, K; Shono, T; Takehara, K; Tsurusaki, T; Yogi, Y, 2011) |
| "Silodosin has a greater impact on improving PI-induced lower urinary tract symptoms than the other two agents." | 5.15 | Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. ( Baba, S; Fujita, T; Hayakawa, K; Ishiyama, H; Kimura, M; Kitano, M; Kotani, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 5.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.14 | Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. ( Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T, 2009) |
| "To investigate the benefit of alpha1-adrenoceptor antagonist naftopidil on the quality of life (QOL) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS)." | 5.14 | Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. ( Araki, K; Awa, Y; Egoshi, K; Ichikawa, T; Komiya, A; Mikami, K; Nakatsu, H; Naya, Y; Ohki, T; Onishi, T; Ota, S; Sato, N; Suzuki, H, 2010) |
| "We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS)." | 5.14 | A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. ( Kazama, T; Kimura, H; Nozaki, T; Okumura, A; Tsuritani, S, 2010) |
| "To examine the effect of alpha 1D/A adrenoceptor inhibitor naftopidil on health-related quality of life (QOL) in men with benign prostatic hyperplasia (BPH)." | 5.13 | Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. ( Awa, Y; Egoshi, K; Hamano, S; Ichikawa, T; Mori, I; Ohki, T; Okano, T; Ota, S; Sakurayama, Y; Suzuki, H, 2008) |
| "The clinical usefulness of naftopidil was evaluated in 122 patients with benign prostatic hyperplasia for urinary tract symptoms and signs, focused in particular on nocturia." | 5.13 | Effect of naftopidil on nocturia after failure of tamsulosin. ( Oh-oka, H, 2008) |
| "To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms." | 5.13 | [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms]. ( Gao, JP; Ge, JP; Gong, J; Ma, HQ; Shang, XJ; Wang, D; Wei, W; Xu, S; Zhang, ZY, 2008) |
| "We conducted a systematic review and meta-analysis to assess the outcomes and complications of naftopidil in treating elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and compared them with those administered with tamsulosin." | 5.12 | Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. ( Chai, Y; Che, X; Cui, Y; Zhang, Y; Zhou, Z, 2021) |
| "To compare the efficacy of two alpha(1)-adrenoceptor antagonists, alpha(1A)-adrenoceptor-selective tamsulosin hydrochloride and alpha(1D)-adrenoceptor-selective naftopidil, in the treatment of lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH)." | 5.12 | Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. ( Deguchi, T; Ishihara, S; Masue, T; Miwa, K; Nishino, Y; Takahashi, Y, 2006) |
| "The present study investigated the efficacy, safety, and utility of starting an alpha(1d)-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 5.12 | Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. ( Kumon, H; Nasu, Y; Takamoto, H; Watanabe, T; Yokoyama, T, 2006) |
| "The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH)." | 5.11 | Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. ( Kamai, T; Sakakibara, R; Tsujii, T; Uchiyama, T; Yamanishi, T; Yasuda, K; Yoshida, K, 2004) |
| "To compare the efficacy and safety of two alpha1a/alpha1d adrenoceptor (AR) antagonists with different affinity for the alpha1AR subtypes, tamsulosin and naftopidil, in the treatment of benign prostatic hyperplasia (BPH)." | 5.11 | Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. ( Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H, 2005) |
| "To evaluate the clinical efficacy and safety of Naftopidil tablet in treating benign prostatic hyperplasia." | 5.10 | [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia]. ( Ju, XB; Su, JT; Wu, HF, 2002) |
| "We studied the efficacy of naftopidil (50 mg/day) on nocturia associated with benign prostatic hyperplasia in 35 patients (62-80 years old)." | 5.10 | [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia]. ( Araki, I; Fukuzawa, S; Hashimura, T; Soeda, T; Sugino, Y; Takeuchi, H; Taki, Y, 2003) |
| "We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for benign prostatic hyperplasia patients." | 5.10 | [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia]. ( Arai, G; Hayashi, T; Hyochi, N; Kageyama, Y; Kawakami, S; Kihara, K; Kobayashi, T; Masuda, H; Okuno, T; Saito, K; Sakai, Y; Suzuki, M, 2002) |
| "Thirty-two patients with voiding dysfunction attributable to symptomatic benign prostatic hyperplasia were treated with naftopidil, an alpha 1-blocker, at doses of 25-75 mg/day for 4-6 weeks." | 5.07 | Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. ( Akimoto, S; Nagashima, K; Shimazaki, J; Tojo, M; Yamanishi, T; Yasuda, K, 1994) |
| " Recently, three drugs (tamsulosin, naftopidil, and silodosin) have been developed in Japan for the treatment of urinary obstruction in patients with benign prostatic hyperplasia." | 4.83 | [Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists]. ( Morishima, S; Muramatsu, I; Suzuki, F; Tanaka, T; Yamamoto, H, 2006) |
| "Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)." | 4.80 | [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000) |
| "First, disproportionality analysis compared the frequency of delirium in the adrenergic alpha-1 receptor antagonists silodosin, tamsulosin, and naftopidil." | 4.31 | Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan. ( Kawakami, Y; Kotake, K; Noritake, Y, 2023) |
| "To assess the efficacy of silodosin as second-line α-blocker monotherapy in patients with lower urinary tract symptoms as a result of benign prostatic hyperplasia." | 3.88 | Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study. ( Haga, K; Hirose, T; Ichihara, K; Iwasawa, A; Masumori, N; Miyao, N; Nishimura, M; Sasamura, H; Suzuki, N; Taguchi, K; Yamaguchi, Y, 2018) |
| "Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa)." | 3.85 | Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver. ( Cai, Y; Fu, X; Guo, J; Guo, Y; Huang, B; Huang, J; Li, A; Liu, X; Rong, Y; Wu, B; Xiao, Q; Yuan, M; Zhang, X; Zhu, L, 2017) |
| "To clarify the influence of naftopidil, an α1D/A -adrenergic receptor antagonist, on the autonomic nervous system, we examined the relation between lower urinary tract symptoms (LUTS) and the plasma monoamine levels before and after naftopidil treatment in benign prostatic hyperplasia (BPH) patients." | 3.83 | Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. ( Ashitomi, K; Kadekawa, K; Matayoshi, Y; Mukoyama, H; Nishijima, S; Onaga, T; Sakumoto, M; Shimabukuro, H; Shimabukuro, S; Sugaya, K, 2016) |
| "The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH)." | 3.77 | [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy]. ( Hashimoto, Y; Hatakeyama, S; Kamimura, N; Kawaguchi, T; Koie, T; Kudo, S; Ohyama, C; Takahashi, S; Yoneyama, T; Yoshikawa, K, 2011) |
| "This study evaluated the 5-year failure rate of naftopidil (NAF) or tamsulosin hydrochloride (TAM) in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/LUTS) and compared the prognostic factor of two alpha(1)-blockers." | 3.76 | Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. ( Honda, S; Iwata, S; Kawachi, Y; Maruyama, O; Noto, K; Sakurai, T; Sugimura, S, 2010) |
| " We studied the efficacy of naftopidil an alpha 1-adrenoreceptor antagonist used for treatment of BPH for improvement of nocturia and consequent sleep disturbance." | 3.76 | [Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia]. ( Iwaki, H; Konishi, T; Narita, M; Okada, Y; Sakano, Y; Soga, H, 2010) |
| "The clinical usefulness and optimal dose of naftopidil were evaluated and discussed in 100 patients with benign prostatic hyperplasia without urinary retention." | 3.75 | Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg. ( Oh-oka, H, 2009) |
| "We examined the effectiveness of naftopidil in 81 patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)." | 3.74 | [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index]. ( Hamano, S; Murakami, S; Nakatsu, H; Naoi, M; Sekiyama, K; Suzuki, N; Tanaka, M, 2007) |
| "We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for 154 symptomatic benign prostatic hyperplasia (BPH) patients who also suffered from overactive bladder (OAB) symptoms." | 3.74 | [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder]. ( Abe, K; Egaway, S; Furuta, A; Ikemoto, I; Kishimoto, K; Kiyota, H; Kosugi, S; Shimomura, T; Shirai, H; Suzuki, Y; Takeuchi, H; Torii, S, 2007) |
| "To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice." | 3.74 | Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007) |
| "We cross-sectionally studied the incidence and impact on quality of life of ejaculatory disorders caused by alpha-1 adrenoceptor antagonists (tamsulosin or naftopidil) in patients with benign prostatic hyperplasia (BPH)." | 3.73 | [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin]. ( Furuya, R; Furuya, S; Hisasue, S; Itoh, N; Masumori, N; Ogura, H; Tsukamoto, T, 2005) |
| "We evaluated the efficacy of an alpha1a/d blocker, naftopidil, on storage symptoms in patients with benign prostatic hyperplasia (BPH), using frequency/volume charts (FVC)." | 3.73 | Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. ( Kawamura, T; Kitamura, T; Matsushima, H; Tajima, A; Takahashi, S; Tominaga, T, 2006) |
| "We compared the urethral and cardiovascular effects of silodosin (selective alpha(1A)-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective alpha(1A)/alpha(1D)-adrenoceptor antagonist) and naftopidil (selective alpha(1D)-adrenoceptor antagonist)." | 3.73 | [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. ( Hayashi, M; Kobayashi, M; Kobayashi, S; Shibata, N; Tadachi, M; Tatemichi, S; Tomiyama, Y; Yamazaki, Y, 2006) |
| "Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months." | 3.72 | [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia]. ( Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Iinuma, M; Kudou, T; Ohinata, M; Suzuki, A, 2003) |
| "To investigate the etiology of overactive bladder (OAB) symptoms during secondary treatment following initial unsuccessful therapy with α1-blockers in benign prostatic hyperplasia (BPH)/OAB patients." | 2.80 | A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia. ( Asai, K; Gotoh, M; Kashiwagi, Y; Kasugai, S; Kato, M; Komatsu, T; Matsukawa, Y; Narita, H; Takai, S; Yamamoto, T, 2015) |
| "Tamsulosin was more effective than naftopidil on intermittency, nocturia and quality of life scores." | 2.73 | Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. ( Hosokawa, Y; Kishino, T; Momose, H; Ono, T; Oyama, N, 2007) |
| "Tamsulosin hydrochloride was more effective in patients with dominant expression of the alpha1a-adrenoceptor subtype, whereas naftopidil was more effective in those with dominant expression of the alpha1d-adrenoceptor subtype." | 2.73 | Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. ( Hayase, M; Hayashi, Y; Kohri, K; Kojima, Y; Kubota, Y; Sasaki, S; Shinoura, H; Tsujimoto, G, 2008) |
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 2.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "Naftopidil is used for benign prostatic hyperplasia management in Japan and a retrospective study brought out a reduced incidence of prostate cancer in patients that had been prescribed this drug." | 2.66 | Drug Repositioning of the α ( Florent, R; N'Diaye, M; Poulain, L, 2020) |
| "Silodosin was found to be more effective than placebo in improving International Prostate Symptom Score (IPSS) and quality of life scores and as effective as other alpha-blockers." | 2.58 | New alpha blockers to treat male lower urinary tract symptoms. ( Gandhi, S; Hwang, EC; Jung, JH, 2018) |
| "Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting." | 2.58 | Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. ( Dahm, P; Gandhi, S; Hwang, EC; Imamura, M; Jung, JH; Kim, MH; Pang, R, 2018) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 2.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| " α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others." | 2.49 | The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. ( Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013) |
| "Among patients with benign prostatic hyperplasia who were treated with a alpha1-adrenoceptor blocker, we administered naftopidil (75 mg/day) for 12 weeks to 85 patients in whom the global severity was evaluated as moderate or severe." | 1.35 | [The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance]. ( Kojima, Y; Miyake, O; Oda, M; Okuyama, A; Tsujihata, M; Uchida, K; Yoshimura, K, 2009) |
| "We examined whether the change of alpha(1)-adrenoceptor (alpha(1)-AR) subtype expression levels in the prostate occurred by administration of the alpha(1d)-AR-subtype-selective antagonist naftopidil to benign prostate hyperplasia (BPH) patients, and discussed the possible alternation of its effectiveness by the chronic administration of alpha(1)-AR antagonists." | 1.34 | Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. ( Hayase, M; Hayashi, Y; Kohri, K; Kojima, Y; Kubota, Y; Sasaki, S; Shinoura, H; Tsujimoto, G, 2007) |
| "Naftopidil was administered for three months to the patients with BPH who had nocturia with a urinary frequency of two or more times." | 1.32 | [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts]. ( Furuhata, A; Hirokawa, M; Hiromoto, Y; Ikeda, A; Kawasaki, C; Masuda, M; Nakayama, K; Satomi, Y; Shiramizu, M, 2004) |
| " KT-611 at a dosage of once or twice a day was evaluated for its effects on 49 patients with benign prostatic hypertrophy." | 1.28 | [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction]. ( Fukaya, Y; Itou, K; Kameoka, H; Kuma, Y; Kumakawa, K; Shiraiwa, Y; Yamaguchi, O; Yamanaka, N; Yokota, T; Yokoyama, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.53) | 18.2507 |
| 2000's | 40 (47.06) | 29.6817 |
| 2010's | 38 (44.71) | 24.3611 |
| 2020's | 4 (4.71) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, F | 1 |
| Chen, H | 1 |
| Xu, J | 1 |
| Liang, X | 1 |
| He, X | 1 |
| Shao, B | 1 |
| Sun, X | 1 |
| Li, B | 1 |
| Deng, X | 1 |
| Yuan, M | 2 |
| Zhan, H | 1 |
| Zhang, S | 1 |
| Li, L | 1 |
| Chen, Z | 1 |
| Cai, Y | 2 |
| Huang, J | 2 |
| Wu, D | 1 |
| Huang, B | 2 |
| Wu, B | 2 |
| Liu, X | 2 |
| Kotake, K | 1 |
| Noritake, Y | 1 |
| Kawakami, Y | 1 |
| Matsukawa, Y | 4 |
| Majima, T | 2 |
| Takai, S | 3 |
| Funahashi, Y | 4 |
| Kato, M | 3 |
| Gotoh, M | 5 |
| Florent, R | 1 |
| Poulain, L | 1 |
| N'Diaye, M | 1 |
| Chai, Y | 1 |
| Zhou, Z | 1 |
| Cui, Y | 1 |
| Che, X | 1 |
| Zhang, Y | 1 |
| Chung, MS | 1 |
| Yoon, BI | 1 |
| Lee, SH | 1 |
| Kwon, SY | 1 |
| Lee, KS | 1 |
| Yoo, TK | 1 |
| Chung, JI | 1 |
| Lee, JY | 1 |
| Hong, JH | 1 |
| Seo, SI | 1 |
| Jung, TY | 1 |
| Kwak, C | 1 |
| Kang, TW | 1 |
| Yun, SJ | 1 |
| Jung, JH | 3 |
| Kim, J | 1 |
| MacDonald, R | 2 |
| Reddy, B | 1 |
| Kim, MH | 2 |
| Dahm, P | 2 |
| Hwang, EC | 2 |
| Gandhi, S | 2 |
| Ichihara, K | 1 |
| Masumori, N | 4 |
| Iwasawa, A | 2 |
| Taguchi, K | 1 |
| Yamaguchi, Y | 1 |
| Nishimura, M | 1 |
| Sasamura, H | 1 |
| Suzuki, N | 2 |
| Haga, K | 1 |
| Miyao, N | 1 |
| Hirose, T | 1 |
| Imamura, M | 1 |
| Pang, R | 1 |
| Takahashi, H | 1 |
| Kubono, S | 1 |
| Taneyama, T | 1 |
| Kuramoto, K | 1 |
| Mizutani, H | 1 |
| Tanaka, N | 1 |
| Yoshida, M | 1 |
| Praus, F | 1 |
| Miernik, A | 1 |
| Akino, H | 1 |
| Ito, H | 1 |
| Nagase, K | 1 |
| Matsuta, Y | 1 |
| Aoki, Y | 2 |
| Hattori, T | 1 |
| Yokoyama, O | 1 |
| Yamaguchi, K | 1 |
| Yoshikawa, T | 1 |
| Hachiya, T | 1 |
| Saito, T | 1 |
| Takahashi, S | 3 |
| Araki, T | 1 |
| Monden, K | 1 |
| Araki, M | 1 |
| Castiglione, F | 1 |
| Benigni, F | 1 |
| Briganti, A | 1 |
| Salonia, A | 1 |
| Villa, L | 1 |
| Nini, A | 1 |
| Di Trapani, E | 1 |
| Capitanio, U | 1 |
| Hedlund, P | 1 |
| Montorsi, F | 1 |
| Tanaka, T | 2 |
| Kuratsukuri, K | 1 |
| Yoshimura, R | 1 |
| Adachi, T | 1 |
| Yamaguchi, T | 1 |
| Ohmachi, T | 1 |
| Yamamoto, S | 1 |
| Nakamura, T | 1 |
| Tamada, S | 1 |
| Nakatani, T | 1 |
| Asai, K | 1 |
| Kasugai, S | 1 |
| Narita, H | 2 |
| Komatsu, T | 2 |
| Kashiwagi, Y | 1 |
| Yamamoto, T | 1 |
| Kadekawa, K | 1 |
| Sugaya, K | 2 |
| Mukoyama, H | 1 |
| Sakumoto, M | 1 |
| Shimabukuro, H | 1 |
| Shimabukuro, S | 1 |
| Matayoshi, Y | 1 |
| Onaga, T | 1 |
| Ashitomi, K | 2 |
| Nishijima, S | 2 |
| Utsunomiya, N | 1 |
| Matsumoto, K | 3 |
| Tsunemori, H | 1 |
| Muguruma, K | 1 |
| Kawakita, M | 1 |
| Kamiyama, Y | 1 |
| Kanamaru, S | 1 |
| Ito, N | 1 |
| Tsukazaki, H | 1 |
| Shirahase, T | 1 |
| Takahashi, T | 1 |
| Ogawa, T | 1 |
| Zhu, L | 2 |
| Fu, X | 1 |
| Zhang, X | 1 |
| Rong, Y | 1 |
| Xiao, Q | 1 |
| Guo, J | 1 |
| Li, A | 1 |
| Guo, Y | 1 |
| Naruoka, T | 1 |
| Suzuki, Y | 2 |
| Furuta, A | 2 |
| Endo, K | 1 |
| Sugaya, S | 1 |
| Egawa, S | 1 |
| Awa, Y | 2 |
| Suzuki, H | 2 |
| Hamano, S | 2 |
| Okano, T | 1 |
| Sakurayama, Y | 1 |
| Ohki, T | 2 |
| Egoshi, K | 2 |
| Ota, S | 2 |
| Mori, I | 1 |
| Ichikawa, T | 3 |
| Oh-oka, H | 2 |
| Ukimura, O | 1 |
| Kanazawa, M | 1 |
| Fujihara, A | 1 |
| Kamoi, K | 1 |
| Okihara, K | 1 |
| Miki, T | 1 |
| Ge, JP | 1 |
| Gong, J | 1 |
| Ma, HQ | 1 |
| Wei, W | 1 |
| Shang, XJ | 1 |
| Zhang, ZY | 1 |
| Xu, S | 1 |
| Wang, D | 1 |
| Gao, JP | 1 |
| Yokoyama, T | 3 |
| Uematsu, K | 1 |
| Watanabe, T | 2 |
| Sasaki, K | 1 |
| Kumon, H | 2 |
| Nagai, A | 2 |
| Tsujihata, M | 1 |
| Yoshimura, K | 1 |
| Kojima, Y | 4 |
| Oda, M | 1 |
| Miyake, O | 1 |
| Uchida, K | 1 |
| Okuyama, A | 1 |
| Sasaki, S | 3 |
| Oda, N | 1 |
| Koshimizu, TA | 1 |
| Hayashi, Y | 3 |
| Kiniwa, M | 1 |
| Tsujimoto, G | 3 |
| Kohri, K | 3 |
| Tsukamoto, T | 3 |
| Furuya, R | 2 |
| Sonoda, T | 1 |
| Mori, M | 1 |
| Garimella, PS | 1 |
| Fink, HA | 1 |
| Wilt, TJ | 1 |
| Kawachi, Y | 2 |
| Sakurai, T | 1 |
| Sugimura, S | 2 |
| Iwata, S | 1 |
| Noto, K | 2 |
| Honda, S | 2 |
| Maruyama, O | 2 |
| Hattori, R | 1 |
| Sassa, N | 1 |
| Komiya, A | 1 |
| Onishi, T | 1 |
| Nakatsu, H | 2 |
| Mikami, K | 1 |
| Sato, N | 1 |
| Araki, K | 1 |
| Naya, Y | 2 |
| Iwaki, H | 1 |
| Narita, M | 1 |
| Soga, H | 1 |
| Sakano, Y | 1 |
| Konishi, T | 1 |
| Okada, Y | 1 |
| Tsuritani, S | 1 |
| Nozaki, T | 1 |
| Okumura, A | 1 |
| Kimura, H | 1 |
| Kazama, T | 1 |
| Hanyu, S | 1 |
| Hatano, A | 1 |
| Nishiyama, T | 1 |
| Obara, K | 1 |
| Takahashi, K | 2 |
| Hara, R | 1 |
| Fukumoto, K | 1 |
| Fujii, T | 1 |
| Jo, Y | 1 |
| Miyaji, Y | 1 |
| Sone, A | 1 |
| Sakai, H | 1 |
| Igawa, T | 1 |
| Onita, T | 1 |
| Furukawa, M | 1 |
| Hakariya, T | 1 |
| Hayashi, M | 2 |
| Matsuya, F | 1 |
| Shida, Y | 1 |
| Nishimura, N | 1 |
| Yogi, Y | 1 |
| Tsurusaki, T | 1 |
| Takehara, K | 1 |
| Nomata, K | 1 |
| Shiraishi, K | 1 |
| Shono, T | 1 |
| Aoki, D | 1 |
| Kanetake, H | 1 |
| Kamimura, N | 1 |
| Hatakeyama, S | 1 |
| Kudo, S | 1 |
| Yoneyama, T | 1 |
| Hashimoto, Y | 1 |
| Koie, T | 1 |
| Yoshikawa, K | 1 |
| Kawaguchi, T | 1 |
| Ohyama, C | 1 |
| Tsumura, H | 1 |
| Satoh, T | 1 |
| Ishiyama, H | 1 |
| Tabata, K | 1 |
| Kotani, S | 1 |
| Minamida, S | 1 |
| Kimura, M | 1 |
| Fujita, T | 1 |
| Kitano, M | 1 |
| Hayakawa, K | 1 |
| Baba, S | 1 |
| Sazuka, T | 1 |
| Kambara, Y | 1 |
| Ishii, T | 1 |
| Nakamura, K | 1 |
| Sakamoto, S | 1 |
| Yamanishi, T | 3 |
| Igarashi, T | 1 |
| Yamaguchi, S | 1 |
| Osanai, H | 1 |
| Numata, A | 1 |
| Watanabe, M | 1 |
| Kakizaki, H | 1 |
| Park, WH | 1 |
| Ishizuka, O | 1 |
| Shirakawa, T | 1 |
| Haraguchi, T | 1 |
| Shigemura, K | 1 |
| Morishita, S | 1 |
| Minayoshi, K | 1 |
| Miyazaki, J | 1 |
| Yamada, Y | 1 |
| Miyake, H | 1 |
| Tanaka, K | 1 |
| Fujisawa, M | 1 |
| Yuan, J | 1 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Qin, X | 1 |
| Yang, K | 1 |
| Mao, C | 1 |
| Masuda, M | 2 |
| Jinza, S | 1 |
| Masuko, H | 1 |
| Asakura, T | 1 |
| Hashiba, T | 1 |
| Miyazato, M | 1 |
| Hatano, T | 1 |
| Ogawa, Y | 1 |
| Ju, XB | 1 |
| Wu, HF | 1 |
| Su, JT | 1 |
| Akasaka, T | 1 |
| Funaki, H | 1 |
| Hirano, S | 1 |
| Ohinata, M | 1 |
| Fujishima, M | 1 |
| Kudou, T | 1 |
| Suzuki, A | 1 |
| Iinuma, M | 1 |
| Sugino, Y | 1 |
| Fukuzawa, S | 1 |
| Takeuchi, H | 2 |
| Taki, Y | 1 |
| Hashimura, T | 1 |
| Soeda, T | 1 |
| Araki, I | 1 |
| Ikemoto, I | 2 |
| Kiyota, H | 2 |
| Ohishi, Y | 1 |
| Abe, K | 2 |
| Goto, H | 1 |
| Kishimoto, K | 2 |
| Miki, K | 1 |
| Nakayama, K | 1 |
| Hiromoto, Y | 1 |
| Hirokawa, M | 1 |
| Satomi, Y | 1 |
| Shiramizu, M | 1 |
| Furuhata, A | 1 |
| Ikeda, A | 1 |
| Kawasaki, C | 1 |
| Yasuda, K | 2 |
| Kamai, T | 1 |
| Tsujii, T | 1 |
| Sakakibara, R | 1 |
| Uchiyama, T | 1 |
| Yoshida, K | 1 |
| Kaplan, SA | 1 |
| Kamihira, O | 1 |
| Kinukawa, T | 1 |
| Ono, Y | 1 |
| Ohshima, S | 1 |
| Origasa, H | 1 |
| Hisasue, S | 1 |
| Ogura, H | 1 |
| Furuya, S | 1 |
| Itoh, N | 2 |
| Tajima, A | 1 |
| Matsushima, H | 1 |
| Kawamura, T | 1 |
| Tominaga, T | 1 |
| Kitamura, T | 1 |
| Bullock, TL | 1 |
| Andriole, GL | 1 |
| Muramatsu, I | 1 |
| Suzuki, F | 1 |
| Yamamoto, H | 1 |
| Morishima, S | 1 |
| Kawabe, K | 2 |
| Tomiyama, Y | 2 |
| Tatemichi, S | 2 |
| Tadachi, M | 1 |
| Kobayashi, S | 2 |
| Kobayashi, M | 2 |
| Yamazaki, Y | 2 |
| Shibata, N | 2 |
| Nishino, Y | 1 |
| Masue, T | 1 |
| Miwa, K | 1 |
| Takahashi, Y | 1 |
| Ishihara, S | 1 |
| Deguchi, T | 1 |
| Nasu, Y | 1 |
| Takamoto, H | 1 |
| Maruyama, I | 1 |
| Kobayashi, K | 1 |
| Maezawa, A | 1 |
| Hanazawa, K | 1 |
| Koizumi, K | 1 |
| Yamashita, R | 1 |
| Sugiyama, Y | 1 |
| Saitoh, T | 1 |
| Oshika, T | 1 |
| Ohashi, Y | 1 |
| Inamura, M | 1 |
| Ohki, K | 1 |
| Okamoto, S | 1 |
| Koyama, T | 1 |
| Sakabe, I | 1 |
| Fujita, Y | 1 |
| Miyoshi, T | 1 |
| Yasuma, T | 1 |
| Naoi, M | 1 |
| Sekiyama, K | 1 |
| Tanaka, M | 1 |
| Murakami, S | 1 |
| Momose, H | 1 |
| Hosokawa, Y | 1 |
| Kishino, T | 1 |
| Ono, T | 1 |
| Oyama, N | 1 |
| Shinoura, H | 2 |
| Hayase, M | 2 |
| Kubota, Y | 2 |
| Kosugi, S | 1 |
| Shimomura, T | 1 |
| Egaway, S | 1 |
| Torii, S | 1 |
| Shirai, H | 1 |
| Hashimoto, J | 1 |
| Li, NC | 1 |
| Wu, SL | 1 |
| Jin, J | 1 |
| Qiu, SP | 1 |
| Kong, CZ | 1 |
| Song, YS | 1 |
| Ye, ZQ | 1 |
| Sun, G | 1 |
| Sun, YH | 1 |
| Sun, YC | 1 |
| Wang, XF | 1 |
| Na, YQ | 1 |
| Tojo, M | 1 |
| Nagashima, K | 1 |
| Akimoto, S | 1 |
| Shimazaki, J | 1 |
| Ikegaki, I | 1 |
| Hayashi, T | 1 |
| Sakai, Y | 1 |
| Saito, K | 1 |
| Arai, G | 1 |
| Hyochi, N | 1 |
| Suzuki, M | 2 |
| Masuda, H | 1 |
| Kawakami, S | 1 |
| Okuno, T | 1 |
| Kobayashi, T | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Yamada, S | 1 |
| Kato, Y | 1 |
| Kimura, R | 1 |
| Mori, R | 1 |
| Maruyama, M | 1 |
| Yamanaka, N | 1 |
| Yamaguchi, O | 1 |
| Kameoka, H | 1 |
| Fukaya, Y | 1 |
| Yokota, T | 1 |
| Shiraiwa, Y | 1 |
| Yokoyama, J | 1 |
| Kumakawa, K | 1 |
| Itou, K | 1 |
| Kuma, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).[NCT02220829] | Phase 3 | 188 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for naftopidil and Adenoma, Prostatic
| Article | Year |
|---|---|
Drug Repositioning of the α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Drug Repositioning; Humans; Male; Na | 2020 |
Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis.
Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prospective Studies; Pr | 2021 |
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; | 2017 |
New alpha blockers to treat male lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naph | 2018 |
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Benzilates; Drug Combinations; Ethamsylate; Humans; Indoles; Lower Uri | 2018 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphth | 2019 |
Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Muscarinic Antagonists; Naphthalenes; Phytotherapy; Pipe | 2014 |
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Prosta | 2009 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostat | 2013 |
Emerging drug therapies for benign prostatic hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Ant | 2006 |
[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Amino Acid Sequence; Animals; | 2006 |
[Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Drug Design; Drug Therapy, Co | 2006 |
[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding, Competitive; Dogs; Humans; Male; Naphthalenes; | 2000 |
40 trials available for naftopidil and Adenoma, Prostatic
| Article | Year |
|---|---|
What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Male; Middle Aged; Naphthalenes; Pip | 2019 |
Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Demography; Humans; Hypertension; Male; Middle A | 2017 |
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; P | 2018 |
Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Indoles; Kallikreins; Lower Urin | 2013 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos | 2013 |
Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Multivariate Analy | 2015 |
A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; | 2015 |
[A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination | 2016 |
Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Male; Middle Aged; Naphthalenes; Pip | 2017 |
Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Pr | 2008 |
Effect of naftopidil on nocturia after failure of tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Follow-Up Studi | 2008 |
Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospectiv | 2008 |
[Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic | 2008 |
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2009 |
Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Naphthalenes; Piperazine | 2009 |
Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Jap | 2011 |
Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Pr | 2010 |
A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Huma | 2010 |
[A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperp | 2010 |
Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Ejaculation; Erectile Dysfunction; | 2011 |
[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2011 |
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Analysis of Variance; Brachytherapy; Humans; Indoles; | 2011 |
Analysis of energy loss mediated by an alpha-1 blocker in patients with benign prostatic hyperplasia using a virtual urethra processed from an endoscopic video image.
Topics: Adrenergic alpha-Antagonists; Endoscopy; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2012 |
α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middl | 2013 |
Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
Topics: Adrenergic alpha-Antagonists; Aged; Asian People; Humans; Indoles; Lower Urinary Tract Symptoms; Mal | 2013 |
[Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
Topics: Adrenergic alpha-Antagonists; Cross-Over Studies; Humans; Indoles; Male; Naphthalenes; Piperazines; | 2012 |
[The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Hu | 2002 |
[Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2003 |
Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Dizziness; Headache; Humans; Hypotension, Or | 2003 |
Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Combinations; Ethamsylate; Humans; Male; Naphthalenes; Phyt | 2004 |
Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Bias; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Naphthalenes; Piperazines; Prospec | 2005 |
Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Humans; Male; Naphthalenes; Piperazines; Pro | 2006 |
Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2006 |
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; | 2006 |
Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination | 2007 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; | 2007 |
Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Biopsy; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Pr | 2008 |
Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic | 1994 |
[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2002 |
32 other studies available for naftopidil and Adenoma, Prostatic
| Article | Year |
|---|---|
Synthesis, structure-activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Molecular Docking Simulation; Piperazines; Pr | 2015 |
Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia.
Topics: Androgens; Animals; Apoptosis; Dihydrotestosterone; Glucuronosyltransferase; Humans; Hyperplasia; Ma | 2022 |
Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan.
Topics: Adrenergic Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Choliner | 2023 |
Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; | 2018 |
Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Epidemiological Monitoring; Humans | 2019 |
α
Topics: Adrenergic alpha-Antagonists; Animals; Dinoprostone; Disease Models, Animal; Diterpenes; Female; Hum | 2019 |
Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biogenic Monoamines; Dopamine; Epinephrine; H | 2016 |
Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Female; Glucuronides; Infusi | 2017 |
[Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Drug Com | 2008 |
Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Comp | 2009 |
[The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; | 2009 |
Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Animals; Apoptosis; Cel | 2009 |
Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Naphthalenes; Pilo | 2010 |
[Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Ag | 2010 |
[Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Benzilates; Cholinergic Antagonists; Drug Res | 2011 |
Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relati | 2002 |
[Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2003 |
[Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Circadian Rhythm; Drug Administration Schedul | 2004 |
[Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Ma | 2005 |
Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; | 2006 |
[Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs | 2006 |
Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Carotid | 2006 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cata | 2007 |
[The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Naphtha | 2007 |
Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Biopsy; Blotting, Weste | 2007 |
[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; | 2007 |
Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Kaplan-Meier Estimate; Male; Naphthalenes; Organ Size; P | 2007 |
Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Binding Sites; Binding, Competitive; Humans; Kinetics; Male; Naphthale | 1992 |
[Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; | 1991 |